Translating research ideas into patient benefits
Investigations are time-consuming and expensive, so greater public funding is needed, according to Prof. George Coukos
Precision oncology is the goal today, not a simple slogan
Prof. Lisa Licitra: “Truly pursuing precision medicine means pushing the boundaries of patient selection using molecular biology and artificial intelligence on all big data, not just molecular information”
Virtual Plenary Debate, a new session not-to-be missed
Presented at the ESMO Virtual Plenaries this year, four key studies in oncology will animate the debate
CheckMate 743 reinforces the role of immunotherapy in first-line mesothelioma
Nearly 1 in 4 patients with pleural malignancy continue to benefit from nivolumab plus ipilimumab at 3 years
Cancer Control Principles
One step back to move forward in oncology workforce
The scope of the oncology care across resource-diverse settings has been long debated.
Cancer Research
Good night for good? Preventing sleeping cancer cells from awakening
Metastases are the main cause of cancer-related deaths. Preventing hibernating cancer cells from awakening therefore represents an urgent, unmet medical need.
Milestone in hereditary breast cancer: PARP inhibition benefits women with early-stage disease
Exciting new data show that adjuvant targeted agent olaparib after chemotherapy can cut the risk of BRCA-mutated breast cancer returning or spreading in women
Cancer Control Principles
Making assumptions about COVID-19 and cancer: a way to harm all
Since its very beginning, the COVID-19 pandemic has pushed people with health vulnerabilities to live in bubbles (symbolically). In parallel, we, as oncology professionals, have accepted more restrictive measures to control the pandemic and while attempting to protect those vulnerable groups, we ended up systematically excluding them from healthcare (literally).
Cancer Research
Conquering cancer: an attainable goal?
Following more than two decades of extraordinary developments and advancements in cancer research – from molecular mechanisms to clinical care to new enabling technologies, we are better equipped than ever before to deliver a much more personalised, targeted form of cancer treatment and care.
Hereditary cancers: diagnosed patients are only the tip of the iceberg
Although knowledge on pathogenic germline variants has improved over the years, researchers are hunting for new genetic causes of cancer to better identify families at higher risk to develop the disease